Aurobindo Pharma Limited has informed the Exchange about completion of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd., a wholly owned subsidiary company
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has told the stock exchange that the US FDA has completed its inspection at Unit III of Eugia Pharma Specialities Ltd., which is a wholly owned subsidiary of the company. Eugia is Aurobindo's arm focused on sterile injectables and is a key contributor to its US business. The company has not shared the outcome of the inspection yet, such as whether any observations (Form 483) were issued or if it was a clean approval. Investors will need to wait for further details from the company to know the impact on production and approvals from this facility.
The stock may see a muted reaction until the inspection outcome is disclosed. A clean inspection would be positive for sentiment, while any significant observations could delay product approvals from this plant and weigh on the stock.